• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX
Click for more information
4.76% 10.0¢

NOXOPHARM LIMITED - Announcements

Market Cap $29.22M  ! watchlist Created with Sketch. Add to my watchlist

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
NOX KZA: Kazia sells stake in NoxopharmPRICE SENSITIVE19/03/19
NOX Noxopharm to expedite Veyonda Clinical ProgramPRICE SENSITIVE21/02/19
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE21/02/19
NOX FNN interview with Nox Chief Medical Officer on Interim DataPRICE SENSITIVE06/02/19
NOX Veyonda and Radiotherapy Delivers Clinical BenefitsPRICE SENSITIVE06/02/19
NOX Appendix 4C - QuarterlyPRICE SENSITIVE29/01/19
NOX Principal Investigator Discusses LuPIN-1 StudyPRICE SENSITIVE14/01/19
NOX NOX Receives $3.26M Federal Govt R&D RebatePRICE SENSITIVE20/12/18
NOX DARRT-1 study advancing on basis of positive clinical dataPRICE SENSITIVE11/12/18
NOX NOX announces Positive Data from CEP-1 Study of VeyondaPRICE SENSITIVE29/11/18
NOX NOX to Present Clinical Data at COSA Annual MeetingPRICE SENSITIVE13/11/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE26/10/18
NOX NOX Subsidiary Announces Important Drug DiscoveryPRICE SENSITIVE24/09/18
NOX NOX to support expanded LuPIN studyPRICE SENSITIVE05/09/18
NOX Appendix 4E and Audited Financial StatementsPRICE SENSITIVE30/08/18
NOX Nyrada-Key progress with cholesterol-lowering drug candidatePRICE SENSITIVE27/08/18
NOX VEYONDA - Registered Trade Mark for NOX66PRICE SENSITIVE20/08/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/07/18
NOX Release of DARRT-1 Preliminary Safety DataPRICE SENSITIVE09/07/18 download Created with Sketch. 239.09KB
NOX Pre-Clinical data confirms Radio-Enhancing potentialPRICE SENSITIVE05/07/18 download Created with Sketch. 169.52KB
NOX End-of-Study Clinical Data shows benefit of NOX66PRICE SENSITIVE05/06/18 download Created with Sketch. 264.42KB
NOX NOX to present at American Society of Clinical OncologyPRICE SENSITIVE22/05/18 download Created with Sketch. 257.98KB
NOX NOX CEO interview on near complete NOX66 chemotherapy trialPRICE SENSITIVE03/05/18
NOX NOX CEO interview on Radiotherapy Clinical ProgramsPRICE SENSITIVE27/04/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE27/04/18
NOX St Vincent's Hospital study passes first milestonePRICE SENSITIVE17/04/18
NOX DARRT-1 Clinical Study commencesPRICE SENSITIVE05/04/18
NOX NOX raises $10.8 M to advance clinical programPRICE SENSITIVE23/03/18
NOX Trading HaltPRICE SENSITIVE21/03/18
NOX Evidence of Abscopal Responses in PatientsPRICE SENSITIVE21/03/18
NOX NOX Reports NOX66 Clinical DataPRICE SENSITIVE06/03/18
NOX Trading HaltPRICE SENSITIVE05/03/18
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE23/02/18
NOX NOX closes $4m capital raising for US subsidiary Nyrada IncPRICE SENSITIVE16/02/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
NOX NOX receives FY17 R&D Tax RebatePRICE SENSITIVE17/01/18
NOX KZA: Kazia Therapeutics and NoxopharmPRICE SENSITIVE27/12/17
NOX EOY Guidance on 2018 NOX66 Clinical Development StrategyPRICE SENSITIVE21/12/17
NOX Response to ASX Price QueryPRICE SENSITIVE14/12/17
NOX Nyrada Inc Opens Capital Raise - Memorandum ReleasedPRICE SENSITIVE01/12/17
NOX NYX-104 delivers Key Proof-of-Concept in Stroke Animal ModelPRICE SENSITIVE29/11/17
NOX Clarification of Incorrect InformationPRICE SENSITIVE23/11/17
NOX Trading HaltPRICE SENSITIVE23/11/17
NOX Promising Interim Clinical Data for NOX66PRICE SENSITIVE20/11/17
NOX Trading HaltPRICE SENSITIVE17/11/17
NOX 1st Patient treated in Lupin Study at St Vincent's HospitalPRICE SENSITIVE16/11/17
NOX UNSW collaboration confirms drug designed for stroke victimsPRICE SENSITIVE03/11/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/10/17
NOX Australian NOX66 - Radiotherapy Study OpensPRICE SENSITIVE27/09/17
NOX Establishment of Nyrada Inc.PRICE SENSITIVE25/09/17
NOX Positive Clinical Outcomes for NOX66 at ESMO ConferencePRICE SENSITIVE12/09/17
NOX Appendix 4E and Audited Financial StatementsPRICE SENSITIVE31/08/17
NOX Important Brain Cancer Findings for NOX66 ProgramPRICE SENSITIVE29/08/17
NOX Reinstatement to Official QuotationPRICE SENSITIVE24/08/17
NOX Noxopharm raises $5.5 million to advance clinical programPRICE SENSITIVE24/08/17
NOX Suspension from Official QuotationPRICE SENSITIVE23/08/17
NOX Trading HaltPRICE SENSITIVE21/08/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
NOX Noxopharm provides update on NOX66 Clinical Trial ProgramPRICE SENSITIVE06/07/17
NOX Idronoxil data provides hope to treat secondary brain cancerPRICE SENSITIVE19/06/17
NOX NOX66 confirmed Non-Toxic. Trial Cleared for Full EnrolmentPRICE SENSITIVE05/06/17
NOX St Vincents Cancer Study to Commence-NOX66 and RadiotherapyPRICE SENSITIVE29/05/17
NOX NOX makes strategic commitment to treatment of rare cancersPRICE SENSITIVE24/05/17
NOX Market Guidance for Next Six MonthsPRICE SENSITIVE02/05/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE27/04/17
NOX NOX Files Patent Application on 'Smart' IdronoxilPRICE SENSITIVE10/04/17
NOX NOX and Monash Uni Collaboration Receives Federal GrantPRICE SENSITIVE27/03/17
NOX Noxopharm and UNSW combine on stroke projectPRICE SENSITIVE16/03/17
NOX NOX researching rare Abscopal ResponsePRICE SENSITIVE03/03/17
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE24/02/17
NOX Brain Cancer Study CommencesPRICE SENSITIVE01/02/17
NOX First NOX66 Clinical Trial to CommencePRICE SENSITIVE31/01/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/01/17
NOX Breakthrough in Delivering Idronoxil into BrainPRICE SENSITIVE23/11/16
NOX Appendix 4C - quarterly-NOX.AX PRICE SENSITIVE31/10/16
NOX Initial Clinic Study Announced and Approved-NOX.AX PRICE SENSITIVE26/10/16
NOX Amendment to Preliminary Final Report-NOX.AX PRICE SENSITIVE30/09/16
NOX Preliminary Final Report-NOX.AX PRICE SENSITIVE31/08/16
NOX Noxopharm to Initiate Radiotherapy Clinical Studies-NOX.AX PRICE SENSITIVE22/08/16
NOX Noxopharm Provides Update on Inaugural Clinical Study-NOX.AX PRICE SENSITIVE10/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX PRICE SENSITIVE08/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX PRICE SENSITIVE08/08/16
NOX KZA: Kazia sells stake in Noxopharm
19/03/19PRICE SENSITIVE
NOX Noxopharm to expedite Veyonda Clinical Program
21/02/19PRICE SENSITIVE
NOX Appendix 4D and Half Year Accounts
21/02/19PRICE SENSITIVE
NOX FNN interview with Nox Chief Medical Officer on Interim Data
06/02/19PRICE SENSITIVE
NOX Veyonda and Radiotherapy Delivers Clinical Benefits
06/02/19PRICE SENSITIVE
NOX Appendix 4C - Quarterly
29/01/19PRICE SENSITIVE
NOX Principal Investigator Discusses LuPIN-1 Study
14/01/19PRICE SENSITIVE
NOX NOX Receives $3.26M Federal Govt R&D Rebate
20/12/18PRICE SENSITIVE
NOX DARRT-1 study advancing on basis of positive clinical data
11/12/18PRICE SENSITIVE
NOX NOX announces Positive Data from CEP-1 Study of Veyonda
29/11/18PRICE SENSITIVE
NOX NOX to Present Clinical Data at COSA Annual Meeting
13/11/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
26/10/18PRICE SENSITIVE
NOX NOX Subsidiary Announces Important Drug Discovery
24/09/18PRICE SENSITIVE
NOX NOX to support expanded LuPIN study
05/09/18PRICE SENSITIVE
NOX Appendix 4E and Audited Financial Statements
30/08/18PRICE SENSITIVE
NOX Nyrada-Key progress with cholesterol-lowering drug candidate
27/08/18PRICE SENSITIVE
NOX VEYONDA - Registered Trade Mark for NOX66
20/08/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
30/07/18PRICE SENSITIVE
NOX Release of DARRT-1 Preliminary Safety Data
09/07/18PRICE SENSITIVE download Created with Sketch. 239.09KB
NOX Pre-Clinical data confirms Radio-Enhancing potential
05/07/18PRICE SENSITIVE download Created with Sketch. 169.52KB
NOX End-of-Study Clinical Data shows benefit of NOX66
05/06/18PRICE SENSITIVE download Created with Sketch. 264.42KB
NOX NOX to present at American Society of Clinical Oncology
22/05/18PRICE SENSITIVE download Created with Sketch. 257.98KB
NOX NOX CEO interview on near complete NOX66 chemotherapy trial
03/05/18PRICE SENSITIVE
NOX NOX CEO interview on Radiotherapy Clinical Programs
27/04/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
27/04/18PRICE SENSITIVE
NOX St Vincent's Hospital study passes first milestone
17/04/18PRICE SENSITIVE
NOX DARRT-1 Clinical Study commences
05/04/18PRICE SENSITIVE
NOX NOX raises $10.8 M to advance clinical program
23/03/18PRICE SENSITIVE
NOX Trading Halt
21/03/18PRICE SENSITIVE
NOX Evidence of Abscopal Responses in Patients
21/03/18PRICE SENSITIVE
NOX NOX Reports NOX66 Clinical Data
06/03/18PRICE SENSITIVE
NOX Trading Halt
05/03/18PRICE SENSITIVE
NOX Appendix 4D and Half Year Accounts
23/02/18PRICE SENSITIVE
NOX NOX closes $4m capital raising for US subsidiary Nyrada Inc
16/02/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
NOX NOX receives FY17 R&D Tax Rebate
17/01/18PRICE SENSITIVE
NOX KZA: Kazia Therapeutics and Noxopharm
27/12/17PRICE SENSITIVE
NOX EOY Guidance on 2018 NOX66 Clinical Development Strategy
21/12/17PRICE SENSITIVE
NOX Response to ASX Price Query
14/12/17PRICE SENSITIVE
NOX Nyrada Inc Opens Capital Raise - Memorandum Released
01/12/17PRICE SENSITIVE
NOX NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
29/11/17PRICE SENSITIVE
NOX Clarification of Incorrect Information
23/11/17PRICE SENSITIVE
NOX Trading Halt
23/11/17PRICE SENSITIVE
NOX Promising Interim Clinical Data for NOX66
20/11/17PRICE SENSITIVE
NOX Trading Halt
17/11/17PRICE SENSITIVE
NOX 1st Patient treated in Lupin Study at St Vincent's Hospital
16/11/17PRICE SENSITIVE
NOX UNSW collaboration confirms drug designed for stroke victims
03/11/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
30/10/17PRICE SENSITIVE
NOX Australian NOX66 - Radiotherapy Study Opens
27/09/17PRICE SENSITIVE
NOX Establishment of Nyrada Inc.
25/09/17PRICE SENSITIVE
NOX Positive Clinical Outcomes for NOX66 at ESMO Conference
12/09/17PRICE SENSITIVE
NOX Appendix 4E and Audited Financial Statements
31/08/17PRICE SENSITIVE
NOX Important Brain Cancer Findings for NOX66 Program
29/08/17PRICE SENSITIVE
NOX Reinstatement to Official Quotation
24/08/17PRICE SENSITIVE
NOX Noxopharm raises $5.5 million to advance clinical program
24/08/17PRICE SENSITIVE
NOX Suspension from Official Quotation
23/08/17PRICE SENSITIVE
NOX Trading Halt
21/08/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
NOX Noxopharm provides update on NOX66 Clinical Trial Program
06/07/17PRICE SENSITIVE
NOX Idronoxil data provides hope to treat secondary brain cancer
19/06/17PRICE SENSITIVE
NOX NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
05/06/17PRICE SENSITIVE
NOX St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
29/05/17PRICE SENSITIVE
NOX NOX makes strategic commitment to treatment of rare cancers
24/05/17PRICE SENSITIVE
NOX Market Guidance for Next Six Months
02/05/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
27/04/17PRICE SENSITIVE
NOX NOX Files Patent Application on 'Smart' Idronoxil
10/04/17PRICE SENSITIVE
NOX NOX and Monash Uni Collaboration Receives Federal Grant
27/03/17PRICE SENSITIVE
NOX Noxopharm and UNSW combine on stroke project
16/03/17PRICE SENSITIVE
NOX NOX researching rare Abscopal Response
03/03/17PRICE SENSITIVE
NOX Appendix 4D and Half Year Accounts
24/02/17PRICE SENSITIVE
NOX Brain Cancer Study Commences
01/02/17PRICE SENSITIVE
NOX First NOX66 Clinical Trial to Commence
31/01/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
30/01/17PRICE SENSITIVE
NOX Breakthrough in Delivering Idronoxil into Brain
23/11/16PRICE SENSITIVE
NOX Appendix 4C - quarterly-NOX.AX
31/10/16PRICE SENSITIVE
NOX Initial Clinic Study Announced and Approved-NOX.AX
26/10/16PRICE SENSITIVE
NOX Amendment to Preliminary Final Report-NOX.AX
30/09/16PRICE SENSITIVE
NOX Preliminary Final Report-NOX.AX
31/08/16PRICE SENSITIVE
NOX Noxopharm to Initiate Radiotherapy Clinical Studies-NOX.AX
22/08/16PRICE SENSITIVE
NOX Noxopharm Provides Update on Inaugural Clinical Study-NOX.AX
10/08/16PRICE SENSITIVE
NOX ASX Market Release - Admission to Official List-NOX.AX
08/08/16PRICE SENSITIVE
NOX ASX Market Release - Admission to Official List-NOX.AX
08/08/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.0¢ 		Change
-0.005(4.76%) 		Mkt cap ! $29.22M
Open High Low Value Volume
11.5¢ 11.5¢ 10.0¢ $6.181K 58.01K

Buyers (Bids)

No. Vol. Price($)
4 42445 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 14000 1
View Market Depth
Last trade - 16.10pm 26/11/2024 (20 minute delay) ?
Last
10.0¢ 		  Change
-0.005 ( 9.09 %)
Open High Low Volume
10.0¢ 10.0¢ 10.0¢ 2527
Last updated 15.59pm 26/11/2024 ?
NOX (ASX) Chart

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have tipped $4.68 billion garbage giant Cleanaway Waste Management Limited (ASX:CWY) as their Hotcopper Hot Stock tip of the week @ especially because it seems to be slowly building towards a euphoric run akin to its mid 20...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.